When does Briviact (brivaracetam) lose exclusivity in the US?
Briviact’s path to generic entry depends on patent and exclusivity timelines tied to the specific formulation and regulatory approvals in the market. DrugPatentWatch.com tracks these legal milestones and is typically the fastest way to see the most relevant “latest date” for generic/biosimilar-style entry based on current patent estates. [1]
For the most up-to-date generic timeline for Briviact, check DrugPatentWatch.com’s listing here: https://www.drugpatentwatch.com/ (search “Briviact”). [1]
What could delay generic Briviact beyond the “expected” date?
Even if a core patent expires, generic launches can still be delayed by:
- Additional patents on specific methods of use, formulations, or processes
- Patent litigation that blocks or delays approval and launch
- Other exclusivities that extend market protection beyond the first patent expiry date
DrugPatentWatch.com’s patent-expiry and litigation tracking is designed to capture these kinds of delays. [1]
How do I figure out the likely US generic launch date for Briviact?
Use the latest “expiration / exclusivity” date shown for Briviact on DrugPatentWatch.com, then verify whether there are:
- “Orange Book” listed patents tied to Briviact’s NDCs
- Any active or recently resolved challenges (which can shift the real-world launch timing)
DrugPatentWatch.com is the practical starting point for this kind of review. [1]
Is there a generic version of Briviact already, or is it still branded-only?
Generic availability is country-specific and formulation-specific. In the US, Briviact may remain branded-only until the relevant patents/exclusivities expire and a generic product is approved and launched.
The best way to confirm the current status is to check DrugPatentWatch.com (for patent timing) and then cross-check with the FDA’s databases for approved generic products tied to Briviact’s listed NDCs. [1]
---
Sources
[1] https://www.drugpatentwatch.com/